TE 8105
Alternative Names: TE-8105Latest Information Update: 08 Jul 2024
At a glance
- Originator Immunwork
- Class Antihypercalcaemics; Drug conjugates; Fatty acids; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
- Preclinical Diabetes mellitus
Most Recent Events
- 07 Jun 2024 Phase-I clinical trials in Obesity in Australia (SC) (NCT06471530)
- 16 Dec 2022 Preclinical trials in Diabetes mellitus in Taiwan (unspecified route) before December 2022 (Immunwork pipeline, December 2022)
- 16 Dec 2022 Preclinical trials in Obesity in Taiwan (unspecified route) before December 2022 (Immunwork pipeline, December 2022)